Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

FDA looks into reassessing criteria around rare disease trials, endpoint selection

As more rare disease treatments make their way to the FDA, the agency on Monday called for further outside input as it grapples with how much efficacy and safety data are sufficient to inform an ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Monday 14 September →